(VIANEWS) – Center Coast MLP & Infrastructure Fund (CEN), Amgen (AMGN), GlaxoSmithKline (GSK) are the highest payout ratio stocks on this list.
We have congregated information concerning stocks with the highest payout ratio at the moment. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. Center Coast MLP & Infrastructure Fund (CEN)
3000% Payout Ratio
Center Coast MLP & Infrastructure Fund is a closed-ended balanced mutual fund launched and managed by Center Coast Capital Advisors, LP. The fund invests in public equity and fixed income markets of North America. It seeks to invest in securities of companies operating in the energy infrastructure sector. The fund primarily invests in equity and debt securities of MLPs and other entities holding primarily general or limited partner or managing member interests in MLPs. For its fixed income portion, the fund seeks to invest in securities across all credit ratings. It employs quantitative analysis with a focus on such factors as cash flow, yield, relative valuation, contract structure, operating risk, competitive environment, growth potential, operational expertise, and strength of business plan to create its portfolio. Center Coast MLP & Infrastructure Fund was formed on September 26, 2013 and is domiciled in the United States.
Earnings Per Share
As for profitability, Center Coast MLP & Infrastructure Fund has a trailing twelve months EPS of $0.03.
PE Ratio
Center Coast MLP & Infrastructure Fund has a trailing twelve months price to earnings ratio of 681. Meaning, the purchaser of the share is investing $681 for every dollar of annual earnings.
Volume
Today’s last reported volume for Center Coast MLP & Infrastructure Fund is 13620 which is 36.05% below its average volume of 21300.
Moving Average
Center Coast MLP & Infrastructure Fund’s value is higher than its 50-day moving average of $19.27 and way higher than its 200-day moving average of $18.29.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 12, 2023, the estimated forward annual dividend rate is 0.9 and the estimated forward annual dividend yield is 4.39%.
2. Amgen (AMGN)
54.04% Payout Ratio
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Earnings Per Share
As for profitability, Amgen has a trailing twelve months EPS of $14.72.
PE Ratio
Amgen has a trailing twelve months price to earnings ratio of 17.82. Meaning, the purchaser of the share is investing $17.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 252.78%.
Previous days news about Amgen (AMGN)
- According to Zacks on Friday, 11 August, "Several companies like Amgen and Novartis have launched their Humira-biosimilars this year. "
3. GlaxoSmithKline (GSK)
45.8% Payout Ratio
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
Earnings Per Share
As for profitability, GlaxoSmithKline has a trailing twelve months EPS of $3.25.
PE Ratio
GlaxoSmithKline has a trailing twelve months price to earnings ratio of 10.74. Meaning, the purchaser of the share is investing $10.74 for every dollar of annual earnings.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 0.9% and positive 28.3% for the next.
Moving Average
GlaxoSmithKline’s worth is under its 50-day moving average of $34.93 and above its 200-day moving average of $34.87.
4. SSR Mining (SSRM)
38.89% Payout Ratio
SSR Mining Inc., together with its subsidiaries, engages in the acquisition, exploration, development, and operation of precious metal resource properties in Turkey and the Americas. The company explores for gold, silver, copper, lead, and zinc deposits. Its projects include the Çöpler Gold mine located in Erzincan, Turkey; the Marigold mine located in Humboldt County, Nevada, the United States; the Seabee Gold Operation located in Saskatchewan, Canada; and the Puna Operations in Jujuy, Argentina. The company was formerly known as Silver Standard Resources Inc. and changed its name to SSR Mining Inc. in August 2017. SSR Mining Inc. was incorporated in 1946 and is based in Denver, Colorado.
Earnings Per Share
As for profitability, SSR Mining has a trailing twelve months EPS of $0.72.
PE Ratio
SSR Mining has a trailing twelve months price to earnings ratio of 20.49. Meaning, the purchaser of the share is investing $20.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.97%.
5. H&R Block (HRB)
38.51% Payout Ratio
H&R Block, Inc., through its subsidiaries, provides assisted income tax return preparation and do-it-yourself (DIY) tax return preparation services and products to the general public primarily in the United States, Canada, and Australia. The company offers assisted income tax return preparation and related services through a system of retail offices operated directly by the company or its franchisees. It also provides Refund Transfers and H&R Block Emerald Prepaid Mastercard, which enables clients to receive their tax refunds; Peace of Mind extended service plans; H&R Block Emerald Advance lines of credit; Tax Identity Shield that provides clients assistance in helping protect their tax identity and access to services to help restore their tax identity; refund advance loans; H&R Block Instant Refund; and H&R Block Pay With Refund services. In addition, the company offers small business financial solutions through its company-owned or franchise offices, and online. H&R Block, Inc. was founded in 1955 and is headquartered in Kansas City, Missouri.
Earnings Per Share
As for profitability, H&R Block has a trailing twelve months EPS of $2.96.
PE Ratio
H&R Block has a trailing twelve months price to earnings ratio of 11.4. Meaning, the purchaser of the share is investing $11.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11402.1%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 31.5% and a drop 12.1% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
H&R Block’s EBITDA is 8.31.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 5, 2023, the estimated forward annual dividend rate is 1.16 and the estimated forward annual dividend yield is 3.51%.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 1’s stock is considered to be overbought (>=80).
Sales Growth
1’s sales growth is 1% for the current quarter and 1% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 1% and 1%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1%, now sitting on 1 for the twelve trailing months.
